{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:19:54Z","timestamp":1784557194446,"version":"3.55.0"},"reference-count":0,"publisher":"Bioscientifica","issue":"9","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>\n                    The current pandemic (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global health challenge with active development of antiviral drugs and vaccines seeking to reduce its significant disease burden. Early reports have confirmed that transmembrane serine protease 2 (TMPRSS2) and angiotensin converting enzyme 2 (ACE2) are critical targets of SARS-CoV-2 that facilitate viral entry into host cells. TMPRSS2 and ACE2 are expressed in multiple human tissues beyond the lung including the testes where predisposition to SARS-CoV-2 infection may exist.\n                    <jats:italic>TMPRSS2<\/jats:italic>\n                    is an androgen-responsive gene and its fusion represents one of the most frequent alterations in prostate cancer. Androgen suppression by androgen deprivation therapy and androgen receptor signaling inhibitors form the foundation of prostate cancer treatment. In this review, we highlight the growing evidence in support of androgen regulation of TMPRSS2 and ACE2 and the potential clinical implications of using androgen suppression to downregulate TMPRSS2 to target SARS-CoV-2. We also discuss the future directions and controversies that need to be addressed in order to establish the viability of targeting TMPRSS2 and\/or ACE2 through androgen signaling regulation for COVID-19 treatment, particularly its relevance in the context of prostate cancer management.\n                  <\/jats:p>","DOI":"10.1530\/erc-20-0165","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T12:57:54Z","timestamp":1591361874000},"page":"R281-R292","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":68,"title":["COVID-19 and androgen-targeted therapy for prostate cancer patients"],"prefix":"10.1530","volume":"27","author":[{"given":"Neil A","family":"Bhowmick","sequence":"first","affiliation":[{"name":"1Department of Medicine, Cedars-Sinai Cancer, Los Angeles, California, USA"},{"name":"2Department of Research, Greater Los Angeles Veterans Administration, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Oft","sequence":"additional","affiliation":[{"name":"3Department of Infectious Diseases, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Pal","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"5Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Figlin","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Cedars-Sinai Cancer, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin M","family":"Posadas","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Cedars-Sinai Cancer, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Freedland","sequence":"additional","affiliation":[{"name":"6Department of Surgery, Cedars-Sinai Cancer, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gong","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Cedars-Sinai Cancer, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/27\/9\/ERC-20-0165.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/27\/9\/ERC-20-0165.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:55:43Z","timestamp":1784555743000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/27\/9\/R281-R292\/25439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":0,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.1530\/erc-20-0165","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}